JP2017515806A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515806A5 JP2017515806A5 JP2016561850A JP2016561850A JP2017515806A5 JP 2017515806 A5 JP2017515806 A5 JP 2017515806A5 JP 2016561850 A JP2016561850 A JP 2016561850A JP 2016561850 A JP2016561850 A JP 2016561850A JP 2017515806 A5 JP2017515806 A5 JP 2017515806A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- poxvirus
- composition according
- oxaliplatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 23
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 5
- 229960001756 oxaliplatin Drugs 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 3
- 229960004768 irinotecan Drugs 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 238000011319 anticancer therapy Methods 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000000311 Cytosine Deaminase Human genes 0.000 claims 1
- 108010080611 Cytosine Deaminase Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 101150067602 F4L gene Proteins 0.000 claims 1
- 101150060895 I4L gene Proteins 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000001461 cytolytic effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 1
- 229960004413 flucytosine Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 108091000036 uracil phosphoribosyltransferase Proteins 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/249,713 | 2014-04-10 | ||
| US14/249,713 US9687515B2 (en) | 2007-11-19 | 2014-04-10 | Poxviral oncolytic vectors |
| PCT/EP2015/057654 WO2015155263A1 (en) | 2014-04-10 | 2015-04-09 | Poxviral oncolytic vectors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017515806A JP2017515806A (ja) | 2017-06-15 |
| JP2017515806A5 true JP2017515806A5 (enExample) | 2018-04-19 |
| JP6657115B2 JP6657115B2 (ja) | 2020-03-04 |
Family
ID=53051793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561850A Active JP6657115B2 (ja) | 2014-04-10 | 2015-04-09 | ポックスウイルス腫瘍細胞崩壊性ベクター |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3129037B1 (enExample) |
| JP (1) | JP6657115B2 (enExample) |
| KR (1) | KR102457060B1 (enExample) |
| CN (1) | CN106413726B (enExample) |
| AU (1) | AU2015243297B2 (enExample) |
| CA (1) | CA2943871C (enExample) |
| DK (1) | DK3129037T3 (enExample) |
| ES (1) | ES2768715T3 (enExample) |
| IL (1) | IL247535B (enExample) |
| WO (1) | WO2015155263A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018091680A1 (en) * | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| CN110461323A (zh) * | 2017-03-31 | 2019-11-15 | 绪方久修 | 溶瘤病毒的增殖方法和抗肿瘤剂 |
| SG11202106898VA (en) * | 2018-12-28 | 2021-07-29 | Transgene Sa | M2-defective poxvirus |
| CN110747174A (zh) * | 2019-10-30 | 2020-02-04 | 青岛宁逸生物科技有限公司 | 一种用于肿瘤治疗的重组病毒 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| KR100242671B1 (ko) * | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5856153A (en) | 1994-11-17 | 1999-01-05 | Cayla | Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases |
| FR2777570A1 (fr) | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
| EP1180157B1 (en) | 1999-05-28 | 2012-11-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| WO2004014314A2 (en) | 2002-08-12 | 2004-02-19 | David Kirn | Methods and compositions concerning poxviruses and cancer |
| JP4672659B2 (ja) | 2003-07-21 | 2011-04-20 | トランジェーヌ、ソシエテ、アノニム | 改善されたシトシンデアミナーゼ活性を有するポリペプチド |
| US8470591B2 (en) | 2004-11-08 | 2013-06-25 | Transgene S.A. | Kit of parts designed for implementing an antitumoral or antiviral treatment in a mammal |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| CA2693623A1 (en) * | 2007-07-18 | 2009-01-22 | Genelux Corporation | Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy |
| KR101542276B1 (ko) * | 2007-11-19 | 2015-08-06 | 트랜스진 에스.에이. | 폭스바이러스성 온콜리틱 벡터 |
| US20100173013A1 (en) * | 2009-01-08 | 2010-07-08 | Denis Drygin | Treatment of neoplastic disorders using combination therapies |
| CA2709292A1 (en) * | 2009-07-10 | 2011-01-10 | The Governors Of The University Of Alberta | Oncolytic viruses and methods for treating neoplastic disorders |
-
2015
- 2015-04-09 EP EP15720276.3A patent/EP3129037B1/en active Active
- 2015-04-09 WO PCT/EP2015/057654 patent/WO2015155263A1/en not_active Ceased
- 2015-04-09 DK DK15720276.3T patent/DK3129037T3/da active
- 2015-04-09 CN CN201580018763.1A patent/CN106413726B/zh active Active
- 2015-04-09 AU AU2015243297A patent/AU2015243297B2/en active Active
- 2015-04-09 ES ES15720276T patent/ES2768715T3/es active Active
- 2015-04-09 JP JP2016561850A patent/JP6657115B2/ja active Active
- 2015-04-09 CA CA2943871A patent/CA2943871C/en active Active
- 2015-04-09 KR KR1020167030784A patent/KR102457060B1/ko active Active
-
2016
- 2016-08-29 IL IL247535A patent/IL247535B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2212423T3 (en) | oncolytic poxvirus vectors | |
| JP2013189456A5 (enExample) | ||
| CA3031416C (en) | Recombinant vaccinia virus and use thereof | |
| JP2012067116A5 (enExample) | ||
| KR20170084034A (ko) | 암 치료용 의약 조성물 제조에서의 아젤니디핀의 용도 | |
| JP2017523777A5 (enExample) | ||
| ES2905478T3 (es) | Virus oncolíticos y moléculas terapéuticas | |
| JP2016506413A5 (enExample) | ||
| ES2946472T3 (es) | Agente antitumoral y potenciador del efecto antitumoral | |
| EP3293201B1 (en) | Combining adenovirus and checkpoint inhibitors for treating cancer | |
| WO2017037292A1 (en) | Combination of a dhodh inhibitor and a her inhibitor for use in the treatment of cancer | |
| JP2013516454A5 (enExample) | ||
| JP2017515806A5 (enExample) | ||
| WO2016210376A3 (en) | Therapeutic peptides and methods of use thereof | |
| JP2016224056A5 (enExample) | ||
| JP2019038796A5 (enExample) | ||
| US20240002547A1 (en) | Therapeutic multi-targeting constructs and uses thereof | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| CN110248671A (zh) | 包含溶瘤痘病毒和nk细胞的治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 | |
| JP2019038797A5 (enExample) | ||
| Parrasia et al. | Targeting pancreatic ductal adenocarcinoma (PDAC) | |
| IL272874B2 (en) | [6r]-mthf an efficient folate alternative in 5-fluorouracil based chemotherapy | |
| JP2018100243A5 (enExample) | ||
| Shih et al. | Bozitinib, a highly selective inhibitor of cMet, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models | |
| CA2943871C (en) | POXVIRAL ONCOLYTIC VECTORS |